In 2012, the overall industry for epilepsy therapeutics in the major developed markets contributed for an approximate share of over $3.1 billion. Furthermore, this market is anticipated to expand at a total CAGR of over 3.3% to cross over $4.2 billion over the forecast period till 2019.
Browse Full Research Report With TOC On “Epilepsy Therapeutics in Major Developed Markets to 2019 – New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns ” at:
Epilepsy is described by recurring seizures as it is a set of long-term neurological disorders. When a group of neurons in brains or nerve cells send wrong signals, episodes of these seizures occur. Depending on the cause of the epilepsy, seizures may possibly be different from primary comprehensive seizures to partial seizures. Patients suffering from epilepsy act weirdly and grumble about strange sensations and emotions. People of all ages are being affected by epilepsy as it is the fourth most common disorder. Doctors prescribe drugs or antiepileptic medicines for the treatment of epilepsy. It depends on the age of the patient seriousness of the seizures and type of seizures to be treated.
Recent approvals of drugs coupled with novel technologies of action are some of the factors attributing to the industry growth of the market. The U.S region contributes to the major market share for over 55% for the total market. In addition, three new anti-epileptic drugs have been permitted in the aforementioned region since 2012. Fycompa, Trobalt and Aptiom are also projected to be launched over the coming years. Moreover, brivaracetam is likely to approve over the coming years. Factors such as improved safety and tolerability of fycoma and trobalt are also contributing significantly owing to the increased interest of prescribers over the past few years.
Browse All Reports of This Category at:
Constant uptake of anti-epileptic drugs of second and third generation is anticipated to attribute towards the revenues in these regions. Although, the market could experience the hindering impact of geriatric competition as a result of novel patent expiries in all the key industries especially for key branded drugs like Lamictal and Keppra.
Key market players operating for epilepsy therapeutics in the major developed markets are Novartis AG, GlaxoSmithKine plc, Shire, Johnson & Johnson Pfizer, Sanofi S.A, Cephalon, Abbot Laboratories, Sunovion Pharmaceuticals, Shire and Valeant Pharamceutical International Inc.
Browse Other Reports By Radiant Insights:
- Acrylonitrile (AN) Companies in China:
- Cyanuric Chloride Companies in China:
About Radiant Insights
Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy. Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake.
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States